Eylea (aflibercept) 8 mg is now listed on the Pharmaceutical Benefits Scheme (PBS)1 for the treatment of neovascular age-related macular degeneration (nAMD) and diabetic macular oedema (DMO) in adults, based on positive results from the pivotal PULSAR and PHOTON studies.2-4
Eylea 8 mg treatment is initiated with one injection per month for three consecutive months, followed by one injection every eight to 16 weeks, based on the ophthalmologist’s judgment of visual and/or anatomic outcomes.2 Treatment with intervals of one month for more than three consecutive months has not been studied.2 Safety of Eylea 8 mg was similar to Eylea 2 mg in both studies, with no new safety signals identified.2-4
Contact: Bayer Account Manager
Please review the Eylea product information before prescribing or contact Bayer Medical Information on (AUS) 1800 008 757.
PBS Information |
|---|
| Eylea 8 mg: Authority required for the treatment of wet age-related macular degeneration and diabetic macular oedema. Eylea 2 mg: Authority required for the treatment of wet age-related macular degeneration, diabetic macular oedema, central retinal vein occlusion, branch retinal vein occlusion, and myopic choroidal neovascularisation. Refer to PBS schedule for full authority required information. |
References
- Pharmaceutical Benefits Scheme, available at: pbs.gov.au/medicine/item/14594D-14626T-14627W-14635G.
- Eylea approved product information.
- Lanzetta P, et al. Lancet 2024. doi: 10.1016/S0140-6736(24)00063-1.
- Brown DM, et al. Lancet 2024. doi: 10.1016/S0140-6736(23)02577-1.
